{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:04:50Z","timestamp":1783940690916,"version":"3.55.0"},"reference-count":30,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: To investigate the structural changes and visual outcomes in eyes with myopic choroidal neovascularization (mCNV) treated with anti-vascular endothelial growth factor (anti-VEGF) compared with fellow eyes over a long-term follow-up period. Methods: A retrospective paired-eye cohort study was conducted, and 51 patients (80.4% female, mean age 51.8 years) with an average follow-up duration of 32.8 months were enrolled. The study included patients with active, treatment-na\u00efve mCNV in one eye and a fellow eye without mCNV. Final visual outcomes and macular retinoschisis (MRS) progression were compared between mCNV eyes treated with intravitreal anti-VEGF injections and fellow eyes. Baseline parameters potentially associated with MRS progression in mCNV eyes were analysed. Results: The final VA increased in mCNV eyes but remained worse than that in fellow eyes (logMAR 0.3 vs. 0.16, p = 0.037). The percentages of treated mCNV eyes and fellow eyes showing MRS progression were similar (18.6% vs. 16.3%, p = 0.782). When mCNV eyes with and without MRS progression were compared (n = 10 and 41, respectively), MRS at baseline was the only significant predictor of MRS progression (70% vs. 17.1%, p = 0.002). A greater percentage of eyes with MRS progression exhibited higher vitreomacular interface (VMI) grading at baseline, although the difference was not statistically significant (40% vs. 14.7%; p = 0.083). Conclusions: Anti-VEGF treatment in mCNV eyes did not increase the incidence of MRS compared with fellow eyes or aggravate MRS. However, the presence of MRS at baseline may increase the risk of MRS progression after treatment, and close monitoring of this subgroup is warranted.<\/jats:p>","DOI":"10.3390\/jcm15145475","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:51:09Z","timestamp":1783936269000},"page":"5475","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Long-Term Evolution of Macular Retinoschisis in Eyes with Myopic Choroidal Neovascularization Treated with Anti-Vascular Endothelial Growth Factors"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0774-5374","authenticated-orcid":false,"given":"Han-Hao","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, Taichung 404, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-7246","authenticated-orcid":false,"given":"Fang-Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan"},{"name":"Department of Ophthalmology, National Taiwan University Hospital, Taipei 100, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: An evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ophtha.2020.07.017","article-title":"Evolution of the Prevalence of Myopia among Taiwanese Schoolchildren: A Review of Survey Data from 1983 through 2017","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/ICL.0000000000000223","article-title":"Complications of Pathologic Myopia","volume":"42","author":"Cho","year":"2016","journal-title":"Eye Contact Lens"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","article-title":"Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia","volume":"63","author":"Ikuno","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/ICL.0000000000000201","article-title":"Epidemiology and Diagnosis of Myopic Choroidal Neovascularization in Asia","volume":"42","author":"Chan","year":"2016","journal-title":"Eye Contact Lens"},{"key":"ref_6","first-page":"3621","article-title":"PREVALENCE, INCIDENCE AND CHARACTERISTICS OF PATIENTS WITH CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA IN A REPRESENTATIVE CANADIAN COHORT","volume":"55","author":"Pickering","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1097\/IAE.0000000000001858","article-title":"Long-Term Outcomes of Ranibizumab Treatment of Myopic Choroidal Neovascularization in East-Asian Patients from the Radiance Study","volume":"38","author":"Tan","year":"2018","journal-title":"Retina"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/eye.2012.97","article-title":"Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization","volume":"26","author":"Lai","year":"2012","journal-title":"Eye"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3760\/cma.j.issn.0366-6999.20133045","article-title":"Retinoschisis and intravitreal ranibizumab treatment for myopic choroidal neovascularization","volume":"127","author":"Huang","year":"2014","journal-title":"Chin. Med. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0002-9394(02)01937-2","article-title":"Prevalence and characteristics of foveal retinal detachment without macular hole in high myopia","volume":"135","author":"Baba","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3928\/23258160-20130219-01","article-title":"Prevalence of macular anatomic abnormalities in high myopia","volume":"44","year":"2013","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ajo.2024.10.003","article-title":"Prevalence, Features, and Risk Factors of Macular Retinoschisis in High Myopic Population: The Beijing Eye Study 2011","volume":"270","author":"Pan","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1097\/IAE.0b013e31825bc0de","article-title":"Myopic traction maculopathy: Pathogenic mechanisms and surgical treatment","volume":"32","author":"Johnson","year":"2012","journal-title":"Retina"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0002-9394(02)02080-9","article-title":"Spontaneous resolution of a shallow detachment of the macula in a highly myopic eye","volume":"135","author":"Polito","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ajo.2013.06.031","article-title":"Natural course of myopic traction maculopathy and factors associated with progression or resolution","volume":"156","author":"Shimada","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s40123-023-00701-4","article-title":"Vitreoretinal Interface Changes After Anti-vascular Endothelial Growth Factor Treatment in Highly Myopic Eyes: A Real-World Study","volume":"12","author":"Tsui","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IAE.0000000000001236","article-title":"Visual Acuity Outcomes of Ranibizumab Treatment in Pathologic Myopic Eyes with Macular Retinoschisis and Choroidal Neovascularization","volume":"37","author":"Ceklic","year":"2017","journal-title":"Retina"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41433-019-0516-x","article-title":"Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after Conbercept therapy: A post-hoc analysis","volume":"34","author":"Zhou","year":"2020","journal-title":"Eye"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","article-title":"International photographic classification and grading system for myopic maculopathy","volume":"159","author":"Kawasaki","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ajo.2006.03.048","article-title":"Natural course of macular retinoschisis in highly myopic eyes without macular hole or retinal detachment","volume":"142","author":"Shimada","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"ref_23","first-page":"190","article-title":"Retinoschisis at macular area in highly myopic eye by optic coherence tomography","volume":"22","author":"Jiang","year":"2006","journal-title":"Yan Ke Xue Bao"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1016\/j.ophtha.2013.07.042","article-title":"The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole","volume":"120","author":"Duker","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ophtha.2015.04.028","article-title":"Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration","volume":"122","author":"Veloso","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1056\/NEJMoa1110823","article-title":"Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes","volume":"367","author":"Stalmans","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1097\/IAE.0000000000000632","article-title":"Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Choroidal Neovascularization Secondary to Pathologic Myopia: Six Years Outcome","volume":"35","author":"Montero","year":"2015","journal-title":"Retina"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1055\/s-0035-1545817","article-title":"Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab","volume":"232","author":"Ladaique","year":"2015","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3760\/cma.j.issn.0366-6999.20132990","article-title":"Intravitreal ranibizumab for the treatment of pathological myopia associated with choroidal neovascularization in Chinese patients","volume":"127","author":"Yang","year":"2014","journal-title":"Chin. Med. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ajo.2010.06.025","article-title":"Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments","volume":"150","author":"Giani","year":"2010","journal-title":"Am. J. Ophthalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5475\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:09:26Z","timestamp":1783937366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":30,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145475"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145475","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}